A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency
CC-94676- (Celgene) Description: A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer Mechanism of Action: Oral Androgen Receptor Degrader Target Patient Population: Prostate Cancer Study Design: Drug is given orally daily.
Description: A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors. Mechanism of Action: CDK4 inhibitor Target Patient Population: Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4
Description: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors Mechanism of action: Targets CEBP-beta, which is a transcription factor controlling multiple cellular processes (differentiation, cell survival and metabolism) Target Patient Population: Breast (HR+), cutaneous melanoma, glioblastoma, prostate cancer Study Design: Drug is administered IV every